IMVT Stock: Price, Earnings History and SEC Filings
Immunovant, Inc. (IMVT) last traded at $29.17, down 1.59% on the latest session and down 13.6% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.75 against an analyst estimate of $-0.66, a miss of 13.6%.
$29.17 -1.59%
1 month-13.65%
52-week high$45.42
52-week low$21.43
Volume1.17M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
IMVT earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-0.75 | $-0.66 | -13.64% |
| Mar 2026 | May 20, 2026 | $-0.73 | $-0.60 | -21.67% |
| Dec 2025 | Feb 6, 2026 | $-0.61 | $-0.72 | +15.28% |
| Sep 2025 | Nov 10, 2025 | $-0.73 | $-0.72 | -1.39% |
IMVT beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for IMVT
SEC filing data is not available right now. You can search for IMVT on SEC EDGAR.
IMVT news
- Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026Oct 21, 2026 · finance.yahoo.com
- Immunovant (IMVT) Stock Looks Stretched On Book Value AloneOct 20, 2026 · finance.yahoo.com
- Immunovant: Batoclimab 2.0 Bull Case Flawed By Mixed Data, Competitive ThreatsOct 20, 2026 · seekingalpha.com
About Immunovant, Inc.
Immunovant, Inc. (IMVT) is a US-listed public company on Nasdaq.